Limits...
In vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell.

Park JC, Lee YJ, Choi HY, Shin YK, Kim JD, Ku SK - Evid Based Complement Alternat Med (2014)

Bottom Line: The results were compared with gemcitabine 160 mg/kg intraperitoneally treated mice (7-day intervals).Platycodin D showed favorable cytotoxic effects on the H520 cells, and also dose-dependently decreased the tumor volumes and weights with increases of apoptotic cells (caspase-3 and PARP immunopositive cells), iNOS and TNF-α immunoreactivities, decreases of COX-2 immunoreactivities in tumor masses.Platycodin D also showed dose-dependent immunostimulatory and anticachexia effects.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary Internal Medicine of Anatomy and Histology, College of Korean Medicine, Daegu Haany University, No. 1 Haanydae-ro, Gyeongsan, Gyeongbuk 712-715, Republic of Korea.

ABSTRACT
Platycodin D is a major pharmacological constituent of Platycodi radix and has showed various pharmacological activities through oxidative stress defense mechanisms. Here, possible antitumor, anticachexia, and immunomodulatory activities of platycodin D were observed on the H520 tumor cell-bearing athymic nude mice after confirming the in vitro cytotoxicity. Platycodin D was orally administered at dose levels of 200, 100, and 50 mg/kg, once a day for 35 days from 15 days after implantation. The results were compared with gemcitabine 160 mg/kg intraperitoneally treated mice (7-day intervals). Platycodin D showed favorable cytotoxic effects on the H520 cells, and also dose-dependently decreased the tumor volumes and weights with increases of apoptotic cells (caspase-3 and PARP immunopositive cells), iNOS and TNF-α immunoreactivities, decreases of COX-2 immunoreactivities in tumor masses. Platycodin D also showed dose-dependent immunostimulatory and anticachexia effects. Gemcitabine showed favorable cytotoxity against H520 tumor cell and related in vivo antitumor effects but aggravated the cancer related cachexia and immunosuppress in H520 tumor cell-bearing athymic nude mice. Taken together, it is considered that oral treatment of platycodin D has potent antitumor activities on H520 cells through direct cytotoxic effects, increases of apoptosis in tumor cells, and immunostimulatory effects and can be control cancer related cachexia.

No MeSH data available.


Related in: MedlinePlus

Tumor volume changes in H520 tumor cell xenograft mice. Values are expressed Mean ± SD of eight mice (mm3). Gemcitabine was intraperitoneally administered at 160 mg/kg, 7-day intervals; platycodin D was orally administered, once a day; aP < 0.01 as compared with tumor-bearing control by LSD test.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4247928&req=5

fig5: Tumor volume changes in H520 tumor cell xenograft mice. Values are expressed Mean ± SD of eight mice (mm3). Gemcitabine was intraperitoneally administered at 160 mg/kg, 7-day intervals; platycodin D was orally administered, once a day; aP < 0.01 as compared with tumor-bearing control by LSD test.

Mentions: Significant (P < 0.01) decreases of the tumor volumes were detected in gemcitabine treated mice as compared with tumor-bearing control from 14 days of administration in this experiment. Platycodin D 200 and 100 mg/kg treated mice also showed significant (P < 0.01 or P < 0.05) decreases of tumor volumes from 14 days after initial administration, and platycodin D 50 mg/kg administered mice also showed significant (P < 0.01 or P < 0.05) decreases of tumor volumes from 21 days of administration, respectively (Figures 4 and 5).


In vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell.

Park JC, Lee YJ, Choi HY, Shin YK, Kim JD, Ku SK - Evid Based Complement Alternat Med (2014)

Tumor volume changes in H520 tumor cell xenograft mice. Values are expressed Mean ± SD of eight mice (mm3). Gemcitabine was intraperitoneally administered at 160 mg/kg, 7-day intervals; platycodin D was orally administered, once a day; aP < 0.01 as compared with tumor-bearing control by LSD test.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4247928&req=5

fig5: Tumor volume changes in H520 tumor cell xenograft mice. Values are expressed Mean ± SD of eight mice (mm3). Gemcitabine was intraperitoneally administered at 160 mg/kg, 7-day intervals; platycodin D was orally administered, once a day; aP < 0.01 as compared with tumor-bearing control by LSD test.
Mentions: Significant (P < 0.01) decreases of the tumor volumes were detected in gemcitabine treated mice as compared with tumor-bearing control from 14 days of administration in this experiment. Platycodin D 200 and 100 mg/kg treated mice also showed significant (P < 0.01 or P < 0.05) decreases of tumor volumes from 14 days after initial administration, and platycodin D 50 mg/kg administered mice also showed significant (P < 0.01 or P < 0.05) decreases of tumor volumes from 21 days of administration, respectively (Figures 4 and 5).

Bottom Line: The results were compared with gemcitabine 160 mg/kg intraperitoneally treated mice (7-day intervals).Platycodin D showed favorable cytotoxic effects on the H520 cells, and also dose-dependently decreased the tumor volumes and weights with increases of apoptotic cells (caspase-3 and PARP immunopositive cells), iNOS and TNF-α immunoreactivities, decreases of COX-2 immunoreactivities in tumor masses.Platycodin D also showed dose-dependent immunostimulatory and anticachexia effects.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary Internal Medicine of Anatomy and Histology, College of Korean Medicine, Daegu Haany University, No. 1 Haanydae-ro, Gyeongsan, Gyeongbuk 712-715, Republic of Korea.

ABSTRACT
Platycodin D is a major pharmacological constituent of Platycodi radix and has showed various pharmacological activities through oxidative stress defense mechanisms. Here, possible antitumor, anticachexia, and immunomodulatory activities of platycodin D were observed on the H520 tumor cell-bearing athymic nude mice after confirming the in vitro cytotoxicity. Platycodin D was orally administered at dose levels of 200, 100, and 50 mg/kg, once a day for 35 days from 15 days after implantation. The results were compared with gemcitabine 160 mg/kg intraperitoneally treated mice (7-day intervals). Platycodin D showed favorable cytotoxic effects on the H520 cells, and also dose-dependently decreased the tumor volumes and weights with increases of apoptotic cells (caspase-3 and PARP immunopositive cells), iNOS and TNF-α immunoreactivities, decreases of COX-2 immunoreactivities in tumor masses. Platycodin D also showed dose-dependent immunostimulatory and anticachexia effects. Gemcitabine showed favorable cytotoxity against H520 tumor cell and related in vivo antitumor effects but aggravated the cancer related cachexia and immunosuppress in H520 tumor cell-bearing athymic nude mice. Taken together, it is considered that oral treatment of platycodin D has potent antitumor activities on H520 cells through direct cytotoxic effects, increases of apoptosis in tumor cells, and immunostimulatory effects and can be control cancer related cachexia.

No MeSH data available.


Related in: MedlinePlus